1. Academic Validation
  2. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain

Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain

  • J Pharm Sci. 2009 Oct;98(10):3509-21. doi: 10.1002/jps.21655.
Boxu Yan 1 Sean Steen David Hambly John Valliere-Douglass Tim Vanden Bos Scott Smallwood Zac Yates Thomas Arroll Yihong Han Himanshu Gadgil Ramil F Latypov Alison Wallace Aiching Lim Gerd R Kleemann Weichun Wang Alain Balland
Affiliations

Affiliation

  • 1 Department of Analytical and Formulation Science, Amgen Inc., 1201 Amgen Court West, Seattle, Washington 98119, USA. byan@amgen.com
Abstract

We investigated the formation and stability of succinimide, an intermediate of deamidation events, in recombinant monoclonal antibodies (mAbs). During the course of an analytical development study of an IgG1 mAbs, we observed that a specific antibody population could be separated from the main product by cation-exchange (CEX) chromatography. The cell-based bioassay measured a approximately 70% drop in potency for this fraction. Liquid chromatography time-of-flight mass spectrometry (LC-TOF/MS) and tandem mass spectrometry (LC-MS/MS) analyses showed that the modified CEX fraction resulted from the formation of a succinimide intermediate at Asn 55 in the complementarity determining region (CDR) of the heavy chain. Biacore assay revealed a approximately 50% decrease in ligand binding activity for the succinimide-containing Fab with respect to the native Fab. It was found that the succinimide form existed as a stable intermediate with a half-life of approximately 3 h at 37 degrees C and pH 7.6. Stress studies indicated that mildly acidic pH conditions (pH 5) favored succinimide accumulation, causing a gradual loss in potency. Hydrolysis of the succinimide resulted in a further drop in potency. The implications of the succinimide formation at Asn 55, a highly conserved residue among IgG1 (mAbs), are discussed.

Figures
Products